Impact of Perioperative Fluid Strategies on Outcomes in Radical Cystectomy: A Systematic Review

Background: Perioperative fluid management plays a critical role in optimizing recovery after radical cystectomy. Various strategies, such as restrictive fluid therapy, goal-directed fluid therapy (GDFT), and warmed fluids, have been studied for their impact on complications and outcomes. However, the optimal approach remains uncertain. Methods: We conducted a systematic review in accordance with PRISMA 2020 guidelines. A PubMed search was performed in January 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies published in English that assessed perioperative fluid strategies in radical cystectomy. Two reviewers independently selected studies, with a third resolving discrepancies. Data were extracted on study characteristics, interventions, and outcomes. Risk of bias was assessed using the Cochrane Risk of Bias Tool. Due to heterogeneity, narrative synthesis was used. Results: Seventeen studies (eight RCTs, nine observational; total n = 3519) were included. Three publications based on a single RCT (n = 167) showed that restrictive fluid therapy with norepinephrine significantly reduced blood loss (p < 0.0001), transfusions (p = 0.0006), complications (p = 0.006), and hospital stay (p = 0.02), with a trend toward fewer 90-day complications (p = 0.12). Six studies (four RCTs, two observational) evaluated GDFT. Doppler- and SVV-based GDFT reduced ileus, nausea, wound infections, and blood loss, although findings on renal function and length of stay were mixed. One RCT showed that warmed fluids reduced transfusion needs (p = 0.028) and hospital stay (p = 0.05). VBFI (Vascular Bed Filling Index)- and aVBFI (adjusted Vascular Bed Filling Index)-guided strategies may lower complications in ileal conduit patients, but evidence remains limited. Conclusions: Restrictive fluid therapy with norepinephrine appears to improve outcomes after radical cystectomy. GDFT and warmed fluids show potential benefits, but findings are inconsistent. Further high-quality trials are needed to define the optimal strategy.